In vitro circuit stability of 5-fluorouracil and oxaliplatin in support of hyperthermic isolated hepatic perfusion

Journal of Extra-Corporeal Technology

Volumn 42, Issue 1, 2010, Pages 75-79

  Colville, Heidi ^a   Dzadony, Ryan ^a   Kemp, Rebecca ^a   Stewart, Stephen ^a   Zeh III, Herbert J ^b,c   Bartlett, David L ^b,c   Holleran, Julianne ^b   Schombert, Kevin ^b   Kosovec, Juliann E ^b   Egorin, Merrill J ^b,c   Beumer, Jan H ^b,d  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Perfusion isolated liver 5 fluorouracil oxaliplatin

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; OXALIPLATIN; PLATINUM; RINGER LACTATE SOLUTION;

ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BLOOD; COLORECTAL CANCER; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STABILITY; DRUG TRANSFORMATION; HUMAN; HYPERTHERMIC THERAPY; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER METASTASIS; LIVER PERFUSION; TANDEM MASS SPECTROMETRY;

EID: 77950788538     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Ausman RK. Development of a technic for isolated perfusion of the liver. NY State J Med. 1961;61:3993-3997.
2. Alexander HR Jr, Libutti SK. Isolated hepatic perfusion for extensive liver metastases. London: W.B. Saunders; 2000;81b:1607-1615.
3. Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery. 2001;2:176-187 (Pubitemid 32158580)
4. Didolkar MS, Jackson AJ, Lesko LJ, et al. Pharmacokinetics of dacarbazine in the regional perfusion of extremities with melanoma. J Surg Oncol. 1996;3:148-158 (Pubitemid 26404554)
5. Shiu MH, Knapper WH, Fortner JG, et al. Regional isolated limb perfusion of melanoma intransit metastases using mechlorethamine (nitrogen mustard). J Clin Oncol. 1986;12:1819-1826.
6. Pontes L, Lopes M, Ribeiro M, Santos JG, Azevedo MC. Isolated limb perfusion with fotemustine after chemosensitization with dacarbazine in melanoma. Melanoma Res. 1997;5:417-419 (Pubitemid 27508733)
7. Ariyan S, Poo WJ, Bolognia J. Regional isolated perfusion of extremities for melanoma: A 20-year experience with drugs other than L-phenylalanine mustard. Plast Reconstr Surg. 1997;4:1023-1029 (Pubitemid 27118288)
8. Murdter TE, Linder A, Friedel G, et al. Pharmacokinetics of cyclophosphamide, adriamycin and adriamycin prodrug (HMR 1928) using an ex vivo isolated perfused human lung model (IHLP). Pneumologie. 2000;11:494-498 [in German].
9. Burt ME, Liu D, Abolhoda A, et al. Isolated lung perfusion for patients with unresectable metastases from sarcoma: A phase I trial. Ann Thorac Surg. 2000;5:1542-1549 (Pubitemid 30434890)
10. Arredondo MA, Chaudhuri B, Kar R, Crist KA, Thomford NR, Chaudhuri PK. Isolated perfusion of pancreas with mitomycin C. Am J Surg. 1990;6:569-574.
11. Huber R, Kruger I, Kuper K, Huber PM, Pichlmaier H. Isolated hyperthermic perfusion with mitoxantrone of melphalan in malignant melanoma of the limb. Am J Surg. 1995;4:345-352.
12. Wile AG, Stemmer EA, Andrews PA, Murphy MP, Abramson IS, Howell SB. Pharmacokinetics of 5-fluorouracil during hyperthermic pelvic isolation-perfusion. J Clin Oncol. 1985;6:849-852.
13. Taeger G, Grabellus F, Podleska LE, Muller S, Ruchholtz S. Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities. Int J Hyperthermia. 2008;3: 193-203. (Pubitemid 351517154)
14. Lienard D, Eggermont AM, Koops HS, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: A multicentre randomized phase II study. Melanoma Res. 1999;5:491-502. (Pubitemid 29494115)
15. Tominaga R, Nakano T, Shibata S, et al. Systemic effects of hyperthermic isolated lower limb perfusion with carboplatin and interferonbeta. Artif Organs. 2001;1:36-41. (Pubitemid 32113556)
16. Pommier RF, Moseley HS, Cohen J, Huang CS, Townsend R, Fletcher WS. Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft-tissue sarcoma and melanoma of the extremities. Am J Surg. 1988;5:667-671.
17. Nakayama J, Takeuchi M, Mayumi H, et al. Hyperthermic isolated limb perfusion with intra-arterial administration of carboplatin and/or interferon-beta for the treatment of malignant melanoma of the leg. J Dermatol. 1994;11:915-922 (Pubitemid 24380679)
18. Zeh HJ III, Brown CK, Holtzman MP, et al. A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer. Ann Surg Oncol. 2009;16:385-394.
19. Laubrock N, Hempel G, Schulze-Westhoff P, Wurthwein G, Flege S, Boos J. The stability of doxorubicin and ldarubicin in plasma and whole blood. Chromatographia. 2008;1-2:9-13.
20. Levi F, Metzger G, Massari C, Milano G. Oxaliplatin: Pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet. 2000; 1:1-21.
21. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989;4:215-237.
22. Kosovec JE, Egorin MJ, Gjurich S, Beumer JH. Quantitation of 5-fluorouracil (5-FU) in human plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008;2:224-230 (Pubitemid 351156135)
23. Erkmen K, Egorin MJ, Reyno LM, Morgan R Jr, Doroshow JH. Effects of storage on the binding of carboplatin to plasma proteins. Cancer Chemother Pharmacol. 1995;3:254-256.
24. D'Argenio DZ, Schumitzky A. ADAPT II User's Guide: Pharmacokinetic/ Pharmacodynamic Systems Analysis Software. Los Angeles: University of Southern California; 1997.
25. Grover A, Alexander HR Jr. The past decade of experience with isolated hepatic perfusion. Oncologist. 2004;6:653-664 (Pubitemid 39546406)
26. Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG. Clinical Oncology. Philadelphia: Elsevier Churchill Livingstone; 2004:1926.
27. Wanebo HJ, Belliveau JF. A pharmacokinetic model and the clinical pharmacology of cis-platinum, 5-fluorouracil and mitomycin-C in isolated pelvic perfusion. Cancer Chemother Pharmacol. 1999;5:427-434.
28. Aigner K, Walther H, Tonn JC, et al. Isolated liver perfusion with 5-fluorouracil (5-FU) in the human. Chirurg. 1982;9:571-573 [in German]. (Pubitemid 13246758)
29. Beumer JH, Courtney J, Stocker D, et al. Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida, January 2007. Clin Colorectal Cancer. 2007;6:407-422.
30. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab Pharmacokinet. 2006;5:357-374.
31. Ploylearmsaeng SA, Fuhr U, Jetter A. How may anticancer chemotherapy with fluorouracil be individualised? Clin Pharmacokinet. 2006;6:567-592.
32. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 1993;24:5970-5976.